Contact Information
Company Information
Annual Revenue
17500000.0
Technologies
Outlook
Microsoft Office 365
Mobile Friendly
Apache
Remote
Keywords
development of immunotherapeutics
tnf superfamily signaling
drug candidates for cancer treatment
cd95
glioblastoma
myelodysplastic syndromes
covid19
biotechnology research
immuno-oncology
therapeutics
oncology
cancer treatment
viral infections
covid-19
drug development
asunercept
tnf superfamily
receptor agonists
clinical trials
progression-free survival
quality of life
overall survival
hera-ligand technology
fusion proteins
anti-tumor immune response
solid tumors
malignant diseases
clinical candidates
preclinical candidates
pipeline
scientific publications
drug candidates
cell death
lymphonpenia
inflammatory response
therapeutic advantages
apoptosis
biologics
cd40 agonist
trail receptor
phase ii trial
orphan drug status
prime designation
biotechnology
drug commercialization
partnerships
academic collaborations
treatment options
patients
healthcare
innovative therapeutics
immune response regulation
signaling pathways
therapeutic applications
hospital & health care
health care
health
wellness & fitness
Get Full Contact Details
Subscribe to reveal email addresses and export contacts.
View Plans